During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners.
The visit aimed to strengthen strategic relationships that support the development and commercialisation of Aurealis’ multi-target cell and gene therapy candidates, AUP-16 for chronic wounds and AUP-55 for oncology indications.
As one of the world’s most important hubs for biotechnology innovation and market, China plays a key role in Aurealis’ global strategy. The team’s visit reflects our continued commitment to expanding international collaborations and globally advancing transformative therapies that address unmet medical needs in chronic wounds, cancer, and inflammation.